Navigation Links
Rigel Announces First Quarter 2008 Financial Results
Date:5/6/2008

of March 31, 2008, Rigel had cash, cash equivalents and available-for-sale securities of $209.7 million compared to $108.3 million at December 31, 2007. In February 2008, Rigel completed a public offering in which it sold 5,000,000 shares of common stock at a public offering price of $27 per share. The aggregate net proceeds of the offering were approximately $127.5 million after deducting underwriting discounts and commissions and offering expenses. Rigel expects to end 2008 with greater than $140.0 million in cash, cash equivalents and available-for-sale securities.

"We finished the first quarter of 2008 with a strong cash position that will be used to fuel our product development programs, including our two upcoming Phase 2b clinical trials of R788 in rheumatoid arthritis," said James M. Gower, chairman and chief executive officer of Rigel. "We expect to begin enrollment for both these clinical trials this quarter."

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's anticipated cash, cash equivalents and available-for-sale secur
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
2. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
3. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
4. Rigel Announces Offering of 4,000,000 Shares of Common Stock
5. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
6. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
7. Rigel Announces Third Quarter 2007 Financial Results
8. BioForm Medical Announces Extension of Lock-Up Period
9. Healthcare Realty Trust Announces First Quarter Results
10. WWMR, Inc. Announces New Website to Showcase Research Case Studies
11. Applied Precision Announces Sale of Life Sciences Business Unit to Senior Management and Telegraph Hill Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Counseling may do little to help young people with ... 66 studies that included nearly 18,000 people 25 and ... drinking problems. Participants in 49 studies attended a single ... the studies attended group sessions or a mix of ... motivational interviewing was used in the studies. This technique ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- College can be ... number of things they can do to make the most ... "a time to adjust, explore, meet new people and learn ... director of student wellness and assessment at St. John,s University ... "Not all learning takes place in the classroom. College ...
(Date:8/22/2014)... 22, 2014 Women with severe disabilities and multiple ... than women with no disabilities or no chronic conditions, ... screened less often than women with moderate disabilities or ... Sara Guilcher, an affiliate scientist with the Li Ka ... Guilcher said women with disabilities often have other measures ...
(Date:8/22/2014)... August 22, 2014 Ticket Down ... in Kalamazoo, New Orleans, Albuquerque and Rapid City. For ... “Long Island Medium,” Theresa Caputo, allows just that. Caputo was ... is part of a close knit family who began to ... a spiritual healer, realized she had a chance to do ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 “Dr. Luciana Show ... Lagana , aka Dr. Luciana, is finding it challenging to ... and while taking care of hundreds of students, so the ... for the show is completed, and she recently entered it ... projects including those of her husband, actor/screenwriter Gregory Graham ...
Breaking Medicine News(10 mins):Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:College Prep 101 2Health News:Women with severe, chronic health issues are screened for breast cancer less often 2Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4
... among young inner-city children appears to be more unpredictable than ... a wise move as a hedge against dangerous flare-ups of ... study from the Johns Hopkins Childrens Center. Current asthma guidelines ... but six months may be too long for many patients, ...
... Johns Hopkins have evidence to explain why the supposedly natural ... factor for life-threatening heart failure. , In a ... Associations (AHA) annual Scientific Sessions in Orlando, Fla., the Hopkins ... and pumping function to assess minute changes in the hearts ...
... erase racial disparities, study suggests , SUNDAY, Nov. 4 (HealthDay ... patients vary widely by race and gender, a new U.S. ... South Carolina, Mt. Pleasant, noted that effective control of hypertension ... about actual rates of treatment and control. , The researchers ...
... from the Framingham Heart Study,link PAT signal with several cardio-vascular ... ... 4 Itamar Medical announced,confirmation of PAT technology by several ... Itamar Medical will now,promote clinical use in the medical community ...
... Carolina to increase the rate of coronary reperfusion (restoring ... significantly improved the quality of care these patients received, ... online to coincide with its release at the American ... in the November 28 print issue of JAMA. ...
... Combination Therapy Due to Flushing, ORLANDO, ... today,showed that Abbott,s SIMCOR(R), an investigational, fixed-dose ... met its primary endpoint of lowering plaque-promoting ... improvements,on other key lipids, LDL "bad" cholesterol, ...
Cached Medicine News:Health News:Urban kids with asthma need more frequent check-ups, Hopkins study suggests 2Health News:Aging heart changes shape, shrinks and loses pumping function too 2Health News:Aging heart changes shape, shrinks and loses pumping function too 3Health News:Poorer Blood Pressure Control in Blacks With Heart Failure 2Health News:New Research Released at AHA Confirms Itamar's PAT Technology to Diagnose Early Cardiovascular Disease 2Health News:Statewide program helps improve quality of care for heart attack 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 3Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 4Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 5
(Date:8/22/2014)...   Zacks Equity Research highlights Epizyme (Nasdaq: EPZM ... Panera (Nasdaq: PNRA - Free Report ) as the Bear ... Amicus Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: ... - Free Report ). Here is a synopsis of ... : The biotech bull market is far from ...
(Date:8/22/2014)... Aug. 22, 2014  Mark Riccio, director of ... facility, is using the online crowd-funding platform Kickstarter ... imaging to researchers and would-be superheros everywhere: "for ... would YOU do if you had Superman,s X-ray ... and explorers everywhere, from elementary through high school ...
(Date:8/22/2014)... , Aug. 22, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... that William E. Saxelby , its President and ... and Chief Executive Officer and as a member of ... 2014.  He will be replaced on an interim basis ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2Landauer, Inc. Announces Executive Management Change 2
... Eli Lilly and Company (NYSE: LLY ) will ... on Wednesday, April 25, 2012.  Lilly will also conduct a ... media to further detail the company,s financial performance. ... to 10:00 a.m. EDT.  Investors, media and the general public ...
... Inc. , a biopharmaceutical company focused on the discovery, ... is in the human nervous system, today announced that ... the treatment of cough has cleared the 30 day ... (FDA).  The Company plans to immediately characterize the pharmacokinetics ...
Cached Medicine Technology:Cerecor Announces Clearance of IND for FP01 2
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
The Elbow Fixator has ontrolled movement about the axis of rotation of the elbow joint. It is minimally invasive and rapidly applied....
... tradition of the original Hoffmann® Fixator, ... surgeon with advanced technology and ease ... snap fit mechanism allows the easy ... or pins providing versatile intraoperative frame ...
... safe and effective nonionic contrast medium well ... Worldwide, more than 250 million doses ... for a wide variety of radiological procedures, ... wide range of iodine concentrations and packaging ...
Medicine Products: